Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist being developed for post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The company holds an exclusive license to the Canadian patent through its broader agreement with Columbia University, which grants Silo rights to develop, manufacture, and commercialize SPC-15 globally.
This Canadian allowance adds to the company's growing intellectual property portfolio, which includes a recently granted European patent covering the same core invention. Corresponding patent applications are also advancing in other international markets. The expansion of patent protection is a critical step for Silo as it seeks to establish a competitive foothold in the mental health therapeutics space, where PTSD affects millions worldwide and existing treatments often have limited efficacy.
Silo intends to pursue the U.S. Food and Drug Administration's streamlined 505(b)(2) regulatory pathway for SPC-15. This approach could shorten clinical timelines and reduce development costs compared to traditional new drug applications, potentially accelerating the drug's availability to patients. By leveraging existing safety and efficacy data for the active ingredient, the 505(b)(2) route enables a more efficient path to approval while still providing the necessary evidence of effectiveness.
The company's focus on underserved conditions, such as PTSD, aligns with a growing recognition of the need for novel psychiatric treatments. SPC-15's intranasal delivery method offers the potential for rapid onset of action and improved patient compliance, which are important factors in managing stress-induced disorders. Silo's collaboration with leading academic institutions enhances its research capabilities and strengthens the scientific foundation of its pipeline.
Beyond SPC-15, Silo is developing other programs, including SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. This diversified portfolio positions the company to address multiple high-need areas in neurology and psychiatry.
The Canadian patent allowance is a key milestone for Silo, as it secures intellectual property protection in a major market and underscores the progress of its lead asset. With a robust patent strategy and a regulatory pathway designed for efficiency, the company is well-positioned to advance SPC-15 through clinical development and potentially bring a new treatment option to patients suffering from PTSD and related conditions.
